LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Microsampling Device Simultaneously Collects Four Volumetrically Identical DBS Blood Samples

By LabMedica International staff writers
Posted on 16 Jun 2023
Print article
Image: The hemaPEN offers a unique approach to capillary sampling (Photo courtesy of Trajan Scientific)
Image: The hemaPEN offers a unique approach to capillary sampling (Photo courtesy of Trajan Scientific)

A cutting-edge device employing volumetric microsampling with capillary and advanced dried blood spot (DBS) technology can collect four equal-volume DBS blood samples from a single finger prick.

Trajan Scientific and Medical’s (Victoria, Australia) hemaPEN is designed to provide a convenient procedure for collecting and storing four DBS samples, thereby enhancing information-rich decision-making. This user-friendly microsampling device can collect four volumetrically identical capillary samples from a single finger stick. The hemaPEN introduces a unique method of capillary sampling with its four integrated capillary tubes within the device for easier handling. The glass capillaries simultaneously draw four samples from a single finger prick, transferring four blood spots onto a DBS cartridge within the hemaPEN.

Designed for one-time use, the hemaPEN is a low-volume sampling device that can collect a sample from any angle, virtually eliminating the risk of under or over-sampling, which benefits users with restricted mobility. Users appreciate the intuitive pen-like design of the hemaPEN and the ability to swiftly collect four microsamples from just one finger prick. Additionally, the hemaPEN ensures the security of samples. After sample collection, users insert the tip of the hemaPEN into its plastic base and push down until a "click" sound is heard, which seals the hemaPEN and transfers the four capillary samples onto four pre-punched DBS papers inside.

Labs that are already equipped for a DBS workflow should find the transition to hemaPEN microsampling methods smooth. Unlike conventional DBS sampling tools, the hemaPEN allows for the collection of an exact and precise fixed micro-volume and is engineered to maintain sample integrity for quantitative analysis. An advantage of the hemaPEN over traditional DBS cards is that it eliminates the need for aliquoting and hole-punching. This is because the hemaPEN collects the four DBS samples onto four pre-punched, industry-standard DBS filter papers within the device. The hemaPEN is suitable for both manual and automated DBS processing workflows. Trajan also provides the hemaPEN opening tool and hemaPEN-QC to assist labs in processing and analyzing DBS microsamples manually or at high throughput. Trajan has received regulatory approval for the clinical use of hemaPEN in Europe and the United Kingdom.

"Our growing range of microsampling technologies allows almost anyone to take an analytically viable sample outside the clinical setting, anytime, anywhere. In our view, that is essential to enable the healthcare systems of the future," said Stephen Tomisich, CEO and founder of Trajan.

Related Links:
Trajan Scientific and Medical 

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TORCH Infections Test
TORCH Panel
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.